Independent HPLC & CoA Verified
COA VerifiedBatch tested for chemical identity, assay purity, sterility, endotoxins and particulate clearance.
Royal Pharma Retatrutide Triple-Agonist (40mg)
Next-generation 40mg triple hormone receptor agonist (GLP-1, GIP, and GCGR) by Royal Pharma engineered for advanced metabolic energy expenditure investigations, glucagon receptor modulation, and hepatic lipid oxidation research (50mg regional formulation available for Portugal protocols).
Technical Specifications
RUO CertifiedAssay Purity
99.4% Purity (HPLC Verified)
Storage Protocol
-20°C (lyophilized), 4°C (reconstituted)
Format / Concentration
40mg / 2mL multiple-dose triple-agonist lyophilized vial
Synthesis Origin
Royal Pharma European Biotech Labs
Access Status
Authorized Researchers Only
Strictly Research Use Only (RUO). Not for diagnostic, veterinary, or human medical procedures. Handled exclusively by authorized laboratory investigators.
Triple Hormone Receptor Agonist (GLP-1 / GIP / GCGR)
Retatrutide is an investigational multi-receptor synthetic peptide sequence exhibiting balanced agonist activity across GLP-1, GIP, and glucagon (GCGR) receptors in metabolic energy expenditure and hepatic lipid oxidation assays.
Provided by Royal Pharma in sealed 40mg lyophilized multi-dose vials (with 50mg EU regional specification support), each lot is released with full chromatogram identity and peptide assay verification.
Receptor Class
GLP-1 / GIP / GCGR
Triple receptor engagement
Vial Capacity
40mg / 50mg EU
Lyophilized reference cake
Purity Standard
99.4% HPLC
Sequence & mass verified
Synthesized and verified under strict aseptic analytical controls with full batch-level chain-of-custody documentation and independent chromatographic identity release testing.